This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection
in a community-based population with largely heterosexual risk. Vaccination did not affect
the viral load or CD4+ count in subjects with HIV infection. Although the results show
only a modest benefit, they offer insight for future research.